Edgewise Therapeutics Earnings Estimate

EWTX Stock  USD 26.26  0.46  1.72%   
The next projected EPS of Edgewise Therapeutics is estimated to be -0.3695 with future projections ranging from a low of -0.4025 to a high of -0.3475. Edgewise Therapeutics' most recent 12-month trailing earnings per share (EPS TTM) is at -1.47. Please be aware that the consensus of earnings estimates for Edgewise Therapeutics is based on EPS before non-recurring items and includes expenses related to employee stock options.
 
Covid
Edgewise Therapeutics is projected to generate -0.3695 in earnings per share on the 31st of December 2024. Edgewise Therapeutics earnings estimates show analyst consensus about projected Edgewise Therapeutics EPS (Earning Per Share). It derives the highest and the lowest estimates based on Edgewise Therapeutics' historical volatility. Many public companies, such as Edgewise Therapeutics, manage the perception of their earnings on a regular basis to make sure that analyst estimates are accurate. Future earnings calculations are also an essential input when attempting to value a firm. By analyzing Edgewise Therapeutics' earnings estimates, investors can diagnose different trends across Edgewise Therapeutics' analyst sentiment over time as well as compare current estimates against different timeframes. Gross Profit is likely to rise to about (1.5 M) in 2025
  
Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Edgewise Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.
For more information on how to buy Edgewise Stock please use our How to Invest in Edgewise Therapeutics guide.

Edgewise Therapeutics Earnings Estimation Breakdown

The calculation of Edgewise Therapeutics' earning per share is based on the data from the past 12 consecutive months, used for reporting the company's financial figures. The next projected EPS of Edgewise Therapeutics is estimated to be -0.3695 with the future projection ranging from a low of -0.4025 to a high of -0.3475. Please be aware that this consensus of annual earnings estimates for Edgewise Therapeutics is based on EPS before non-recurring items and includes expenses related to employee stock options.
Last Reported EPS
-0.36
-0.4
Lowest
Expected EPS
-0.3695
-0.35
Highest

Edgewise Therapeutics Earnings Projection Consensus

Suppose the current estimates of Edgewise Therapeutics' value are higher than the current market price of the Edgewise Therapeutics stock. In this case, investors may conclude that Edgewise Therapeutics is overpriced and will exhibit bullish sentiment. On the other hand, if the present value is lower than the stock price, analysts may conclude that the market undervalues the equity. These scenarios may suggest that the market is not as efficient as it should be at the estimation time, and Edgewise Therapeutics' stock will quickly adjusts to the new information provided by the consensus estimate.
Number of AnalystsHistorical AccuracyLast Reported EPSEstimated EPS for 31st of December 2024Current EPS (TTM)
793.47%
-0.36
-0.3695
-1.47

Edgewise Therapeutics Earnings per Share Projection vs Actual

Actual Earning per Share of Edgewise Therapeutics refers to what the company shows during its earnings calls or quarterly reports. The Expected EPS is what analysts covering Edgewise Therapeutics predict the company's earnings will be in the future. The higher the earnings per share of Edgewise Therapeutics, the better is its profitability. While calculating the Earning per Share, we use the weighted ratio, as the number of shares outstanding can change over time.

Edgewise Therapeutics Estimated Months Earnings per Share

For an investor who is primarily interested in generating an income out of investing in entities such as Edgewise Therapeutics, the EPS ratio can tell if the company is intending to increase its current dividend. Although EPS is an essential tool for investors, it should not be used in isolation. EPS of Edgewise Therapeutics should always be considered in relation to other companies to make a more educated investment decision.

Edgewise Quarterly Analyst Estimates and Surprise Metrics

Earnings surprises can significantly impact Edgewise Therapeutics' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
Reported
Fiscal Date
Estimated EPS
Reported EPS
Surprise
2024-11-07
2024-09-30-0.37-0.360.01
2024-08-08
2024-06-30-0.34-0.340.0
2024-05-09
2024-03-31-0.39-0.330.0615 
2024-02-22
2023-12-31-0.43-0.47-0.04
2023-11-09
2023-09-30-0.4-0.41-0.01
2023-08-10
2023-06-30-0.4-0.340.0615 
2023-05-11
2023-03-31-0.36-0.360.0
2023-02-23
2022-12-31-0.34-0.310.03
2022-11-03
2022-09-30-0.36-0.340.02
2022-08-04
2022-06-30-0.32-0.320.0
2022-05-11
2022-03-31-0.28-0.3-0.02
2022-02-24
2021-12-31-0.25-0.26-0.01
2021-11-10
2021-09-30-0.22-0.26-0.0418 
2021-08-09
2021-06-30-0.18-0.21-0.0316 
2021-05-13
2021-03-31-0.16-4.37-4.212631 
null
nullnullnullnull

About Edgewise Therapeutics Earnings Estimate

The earnings estimate module is a useful tool to check what professional financial analysts are assuming about the future of Edgewise Therapeutics earnings. We show available consensus EPS estimates for the upcoming years and quarters. Investors can also examine how these consensus opinions have evolved historically. We show current Edgewise Therapeutics estimates, future projections, as well as estimates 1, 2, and three years ago. Investors can search for a specific entity to conduct investment planning and build diversified portfolios. Please note, earnings estimates provided by Macroaxis are the average expectations of expert analysts that we track. If a given stock such as Edgewise Therapeutics fails to match professional earnings estimates, it usually performs purely. Wall Street refers to that as a 'negative surprise.' If a company 'beats' future estimates, it's usually called an 'upside surprise.'
Please read more on our stock advisor page.
Last ReportedProjected for Next Year
Retained Earnings-220.3 M-209.3 M
Retained Earnings Total Equity-130.1 M-136.6 M
Earnings Yield(0.17)(0.16)
Price Earnings Ratio(6.26)(6.58)
Price Earnings To Growth Ratio(0.01)(0.01)

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Edgewise Stock Analysis

When running Edgewise Therapeutics' price analysis, check to measure Edgewise Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Edgewise Therapeutics is operating at the current time. Most of Edgewise Therapeutics' value examination focuses on studying past and present price action to predict the probability of Edgewise Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Edgewise Therapeutics' price. Additionally, you may evaluate how the addition of Edgewise Therapeutics to your portfolios can decrease your overall portfolio volatility.